Intangible Assets, Net (Details) - USD ($) |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
Dec. 31, 2025 |
May 31, 2025 |
Dec. 31, 2024 |
May 31, 2024 |
Dec. 31, 2023 |
Nov. 30, 2025 |
|
| Intangible Assets, Net [Line Items] | ||||||
| Amortization expenses for finite-lived intangible assets | $ 19,219 | |||||
| Intangible assets | ||||||
| DiamiR Biosciences Corp. [Member] | ||||||
| Intangible Assets, Net [Line Items] | ||||||
| Impairment loss on intangible assets | ||||||
| Intangible assets | $ 197,761 | $ 197,761 | ||||
| Research and Development Expense [Member] | ||||||
| Intangible Assets, Net [Line Items] | ||||||
| Impairment loss on intangible assets | $ 519,496 | |||||
| Other Operating Expenses [Member] | ||||||
| Intangible Assets, Net [Line Items] | ||||||
| Impairment loss on intangible assets | $ 128,128 | $ 1,841 | ||||
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|